Dasatinib and the Risk of Pulmonary Arterial Hypertension
Published Online: Friday, October 21, 2011
In this podcast, Jennifer Shepherd, a pharmacist in the FDA’s Division of Drug Information, discusses the increased risk of pulmonary arterial hypertension associated with Sprycel (dasatinib), a drug indicated to treat leukemia.
To access the podcast, click here
Your comments are valuable to us. Thank you.
Sorry, you must be logged in and registered to post a comment.
To login, click To register, click here.